Expected High Growth Market Segments in Molecular Diagnostic Testing
Tests for hepatitis, nucleic acid blood testing and respiratory testing are among the fast-growing segments of molecular testing in 2018, according to a new report from Kalorama Information. will exceed the average for revenue growth in molecular IVD, according to a new Kalorama Information report. Average molecular IVD products will see six percent growth, the areas identified will be higher, over the next five years. These are among the findings in Kalorama Information’s report, Expected High-Growth Market Segments in Molecular Testing.
Molecular testing provides fast and accurate results and the presence of molecular tests has disrupted several testing markets over the past decade and a half, However, some segments have thrived and others are seeing mature growth levels. Kalorama Information report details the highest revenue growth areas of molecular testing, as considered by manufacturers of IVD instruments, reagents and supplies.
Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices. The primary technologies for clinical molecular diagnostics include nucleic acid amplification tests (NAATs) based on real-time PCR (qPCR) and other amplification-detection protocols; direct nucleic acid probe tests such as in situ hybridization (ISH) and its fluorescent ISH (FISH); next-generation sequencing (NGS); amplification followed by probe-based hybridization on arrays (or microarrays); and other related methods.
The report covers both high-growth product segments and regional markets of significance.
Kalorama Information’s report reveals:
•High-Growth Areas in Molecular Infectious Disease Testing
•High-Growth Areas in Molecular Cancer Testing
•High-Growth Areas in Other Molecular Testing
•Overview of Molecular Test Technologies.
•Top Companies in High-Growth Molecular Testing Markets
•Conclusions and Projections to 2021
Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices.
The report is based on the findings in Kalorama Information's Molecular Diagnostics 7th Edition report.
The major applications of clinical molecular diagnostics include: Infectious disease diagnostics such as molecular microbiology and virology, including the detection, identification, quantification and nucleic-acid based resistance or susceptibility profiling of pathogens; Blood Transfusion Diagnostics, nucleic acid screening (NAT) of donated blood, often pooled samples, for the detection of active infections responsible for transfusion transmitted infections (TTIs); ancillary market for molecular immunohematology or blood typing; Histology / cytology diagnostics , which is largely synonymous with in situ hybridization (ISH) methods that use direct hybridization of chromogenic (CISH) or fluorescent (FISH) nucleic acid probes within slided tissue or suspended cell samples viewed under microscopy;Molecular Cancer Diagnostics, which are tissue, blood and urine samples can be assayed using nucleic acid amplification tests (NAATs) or sequencing to diagnose, prognose and identify key mutations for targeted therapies; future; Transplant diagnostics - various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, as well as post-transplant monitoring.
The report also covers Inherited disease diagnostics - diagnosis of rare genetic diseases andother inherited traits including pharmacodiagnostic (pharmacokinetic) traits;major area of application is thrombophilia markers and anticoagulant response markers
Search inside this report
Departmental Site License (one location, 10 users)